OraSure Technologies (NASDAQ:OSUR) Stock Price Down 5%

OraSure Technologies, Inc. (NASDAQ:OSUR) shares traded down 5% on Wednesday . The company traded as low as $7.02 and last traded at $7.19, 577,628 shares changed hands during trading. A decline of 11% from the average session volume of 648,395 shares. The stock had previously closed at $7.57.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research lowered shares of OraSure Technologies from a “hold” rating to a “sell” rating in a report on Tuesday, July 9th. BidaskClub lowered shares of OraSure Technologies from a “sell” rating to a “strong sell” rating in a report on Wednesday. Finally, Canaccord Genuity reissued a “hold” rating and set a $7.00 target price on shares of OraSure Technologies in a report on Wednesday. Three research analysts have rated the stock with a sell rating and one has assigned a hold rating to the stock. The company has a consensus rating of “Sell” and a consensus price target of $7.00.

The company has a quick ratio of 6.13, a current ratio of 6.99 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $467.26 million, a PE ratio of 14.37, a P/E/G ratio of 2.41 and a beta of 1.19. The business has a fifty day moving average of $8.51.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.04. The firm had revenue of $38.83 million for the quarter, compared to the consensus estimate of $41.48 million. OraSure Technologies had a net margin of 11.83% and a return on equity of 7.81%. The company’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.07 EPS. As a group, sell-side analysts anticipate that OraSure Technologies, Inc. will post 0.25 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new position in shares of OraSure Technologies in the 2nd quarter worth approximately $25,000. Roble Belko & Company Inc acquired a new position in shares of OraSure Technologies in the 1st quarter worth approximately $29,000. BSW Wealth Partners acquired a new position in shares of OraSure Technologies in the 2nd quarter worth approximately $29,000. Parallel Advisors LLC acquired a new position in shares of OraSure Technologies in the 1st quarter worth approximately $33,000. Finally, Quantamental Technologies LLC acquired a new position in shares of OraSure Technologies in the 1st quarter worth approximately $56,000. Hedge funds and other institutional investors own 91.36% of the company’s stock.

About OraSure Technologies (NASDAQ:OSUR)

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Further Reading: Google Finance Portfolio Workaround

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit